INVITAE CORP. DL-,0001 WKN: A14NKG ISIN: US46185L1035 Kürzel: NVTA Forum: Aktien Thema: Hauptdiskussion
Kommentare 2.822
1
12Bobby34,
09.11.2022 15:53 Uhr
0
leicht verdientes geld. heut abend stehts wieder unter 2,70 ;)
1
12Bobby34,
09.11.2022 15:52 Uhr
0
2,95 nochmal short nachgelegt :)
M
Mn66,
09.11.2022 15:51 Uhr
0
Krasser Anstieg
1
12Bobby34,
09.11.2022 15:48 Uhr
0
2,80 neuer Short ;)
Tampa,
09.11.2022 15:44 Uhr
0
Sieht gut aus 👍
1
12Bobby34,
09.11.2022 15:33 Uhr
0
uiiii, sehr schöne neue Shorteinstiege :)
B
Blocki89,
09.11.2022 14:20 Uhr
0
Hier passiert nix, wahrscheinlich sehr schlechte Zahlen
1
L
Lion1620,
09.11.2022 6:46 Uhr
0
https://www.fool.com/earnings/call-transcripts/2022/11/08/invitae-nvta-q3-2022-earnings-call-transcript/
S
Sladdi,
08.11.2022 23:08 Uhr
1
Alles sehr positiv mal sehen was kommt, die setzen alles um und nach plan 👍
Nice01,
08.11.2022 22:44 Uhr
0
Voila
Nice01,
08.11.2022 22:44 Uhr
1
Third Quarter 2022 Highlights
Generated revenue of $133.5 million, a 16.7% increase compared to $114.4 million in the third quarter of 2021.
GAAP gross profit was $16.6 million, and non-GAAP gross profit was $61.2 million.
GAAP gross margin was 12.4%. Non-GAAP gross margin was 45.9% as compared with 40.1% in the second quarter of 2022 and 35.6% in the third quarter of 2021.
Cash, cash equivalents, restricted cash and marketable securities were $596.0 million as of September 30, 2022, compared to $736.8 million as of June 30, 2022. Cash burn was $151.5 million, which excludes a $9.7 million inflow from sales under our ATM facility. Our cash burn was $108.3 million after adjustments for outflows of $29.1 million related to realignment and $14.1 million related to contingent consideration held for past M&A transactions.
Total active healthcare provider accounts totaled 20,831 as of September 30, an increase of approximately 20% year-over-year.
Active pharmaceutical and commercial partnerships grew to 234, an increase of approximately 38% year-over-year, due to revenue growth from lab services, data services to pharmaceutical, health systems and other partners.
Revenue per patient was $505, an increase of approximately 8% from $468 in the third quarter of 2021.
Total patient population as of September 30 is more than 3.3 million with over 62% available for data sharing.
L
Lion1620,
08.11.2022 22:17 Uhr
1
Invitae geht grade hoch angeblich sind die Zahlen gut
L
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | BioNTech Hauptdiskussion | -0,08 % | |
2 | EVOTEC Hauptdiskussion | +0,24 % | |
3 | MicroStrategy | +0,43 % | |
4 | Trading- und Aktien-Chat | ||
5 | DAX Hauptdiskussion | +0,09 % | |
6 | Börsen Comedy | ||
7 | Ripple Hauptdiskussion | +34,89 % | |
8 | Exela 2023 sachliches Forum | +5,36 % | |
9 | GAMESTOP Hauptdiskussion | +0,56 % | |
10 | XRP zu USD Hauptdiskussion | +30,80 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | BioNTech Hauptdiskussion | -0,08 % | |
2 | EVOTEC Hauptdiskussion | +0,24 % | |
3 | MicroStrategy | +0,43 % | |
4 | GAMESTOP Hauptdiskussion | +0,56 % | |
5 | Exela 2023 sachliches Forum | +5,36 % | |
6 | 2.0 | -0,70 % | |
7 | NIO INC.A S.ADR DL-,00025 Hauptdiskussion | ±0,00 % | |
8 | NVIDIA Hauptdiskussion | +0,70 % | |
9 | RENK (für normale, sachliche Kommunikation!) | +0,27 % | |
10 | Nantkwest / Immunitybio -> IBRX | +1,17 % | Alle Diskussionen |